Investor Relations

Press Releases

 
Press Releases
  Date Title and Summary View
Apr 2, 2013
CONTACT: Lauren Silvernail Chief Financial Officer and EVP Corporate Development 510-742-3415 lsilvernail@revance.com NEWARK, California — April 2, 2013 — Revance Therapeutics, Inc. (Revance), a privately held specialty biopharmaceutical company developing novel botulinum toxin products for use in aestheti...
Mar 25, 2013
CONTACT: Revance Therapeutics, Inc. Niquette L. Hunt Senior Vice President, Commercial Development NEWARK, California—March 25, 2013 — Revance Therapeutics, Inc. (Revance) today announced the appointment of Lauren Silvernail as Chief Financial Officer and Executive Vice President of Corporate Development effect...
Oct 8, 2012
CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif.—October 8, 2012 — Revance Therapeutics, Inc. (Revance) today announced a settlement and termination agreement for its contractual relationships with Medicis Pharmaceutical Corporation (NYSE:MRX) concerni...
Jun 10, 2011
CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif. – June 10, 2011 – Revance Therapeutics, Inc. (“Revance”) today announced the closing of a $45 million financing led by Essex Woodlands Health Ventures and new investor, NovaQuest Capital (Nov...
Oct 22, 2010
CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif. – October 22, 2010 – Revance Therapeutics, Inc. (“Revance”) today announced that the results of two Phase 2b clinical trials on RT001, a topical botulinim toxin type A which is under investig...
Jan 4, 2010
CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif. – January 4, 2010 – Revance Therapeutics, Inc. (“Revance”) today announced the first $25M closing of a $35 million Series D financing. The round was led by Essex Woodlands Health Ventures Fun...
Jul 28, 2009
CONTACT: Medicis Pharmaceutical Corporation Kara Stancell Executive Director, Investor Relations & Corporate Communications (480) 291-5854 Revance Therapeutics, Inc. Niquette Hunt Senior Vice President, Commercial Development (510) 742-3464 SCOTTSDALE, Ariz. and NEWARK, Calif. – July 2...
Jul 9, 2009
CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif. — July 9, 2009 — Revance Therapeutics, Inc. (“Revance”) today announces that RT001, a topical botulinum toxin type A, under investigation for the treatment of crow’s feet wrinkles, demo...
Nov 18, 2008
CONTACT: Revance Therapeutics, Inc. Niquette Hunt Vice President, Marketing & Business Development (510) 742-3400 Newark, Calif. November 18, 2008 — Revance Therapeutics, Inc. (“Revance”) today announced an agreement with Leader Ventures and Horizon Technology Finance that will provide $8 million...
Page: FirstPrevious ...
10
= add release to Briefcase
Shareholder Tools